Bulletin of the Korean Chemical Society

Korean Chemical Society (대한화학회)
권호 표지
DOI QR코드

DOI QR Code

Structure-Activity Relationship of Novel Lactam Based Histone Deacetylase Inhibitors as Potential Anticancer Drugs

  • Yang, Jee-Sun (Translational Research Center for Protein Function Control, Department of Biotechnology, Yonsei University) ;
  • Chun, Tae-Gyu (Electronic Chemical Materials Research Institute, Cheil Industries Inc.) ;
  • Nam, Ky-Youb (Research Institute of Bioinformatics & Molecular Design) ;
  • Kim, Hwan-Mook (College of Pharmacy, Gachon University of Medicine and Science) ;
  • Han, Gyoon-Hee (Translational Research Center for Protein Function Control, Department of Biotechnology, Yonsei University)
  • Received : 2011.09.26
  • Accepted : 2012.03.12
  • Published : 2012.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Cosio, B. G.; Mann, B.; Ito, K.; Jazrawi, E.; Barnes, P. J.; Chung, K. F.; Adcock, I. M. Am. J. Respir. Crit. Care Med. 2004, 170(2), 141. https://doi.org/10.1164/rccm.200305-659OC
  2. Kouzarides, T. Curr. Opin. Genet. Dev. 1999, 9(1), 40. https://doi.org/10.1016/S0959-437X(99)80006-9
  3. Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. J. Med. Chem. 2003, 46(23), 4826. https://doi.org/10.1021/jm034167p
  4. Halkidou, K.; Gaughan, L.; Cook, S.; Leung, H. Y.; Neal, D. E.; Robson, C. N. Prostate. 2004, 59(2), 177. https://doi.org/10.1002/pros.20022
  5. Osada, H.; Tatematsu, Y.; Saito, H.; Yatabe, Y.; Mitsudomi, T.; Takahashi, T. Int. J. Cancer 2004, 112(1), 26. https://doi.org/10.1002/ijc.20395
  6. Marks, P. A. Oncogene 2007, 26(9), 1351. https://doi.org/10.1038/sj.onc.1210204
  7. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. J. Med. Chem. 2008, 51(6), 1505. https://doi.org/10.1021/jm7011408
  8. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K. H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. Cancer Res. 2002, 62(17), 4916.
  9. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Int. J. Cancer 2007, 121(5), 1138. https://doi.org/10.1002/ijc.22751
  10. The Huntington Study Group. Neurology 2001, 57(3), 397.
  11. Leoni, F.; Fossati, G.; Lewis, E. C.; Lee, J. K.; Porro, G.; Pagani, P.; Modena, D.; Moras, M. L.; Pozzi, P.; Reznikov, L. L.; Siegmund, B.; Fantuzzi, G.; Dinarello, C. A.; Mascagni, P. Mol. Med. 2005, 11(1-12), 1.
  12. Kim, H. M.; Hong, S. H.; Kim, M. S.; Lee, C. W.; Kang, J. S.; Lee, K.; Park, S. K.; Han, J. W.; Lee, H. Y.; Choi, Y.; Kwon, H. J.; Han, G. Bioorg. Med. Chem. Lett. 2007, 17(22), 6234. https://doi.org/10.1016/j.bmcl.2007.09.034
  13. Kim, H. M.; Lee, K.; Park, B. W.; Ryu, D. K.; Kim, K.; Lee, C. W.; Park, S. K.; Han, J. W.; Lee, H. Y.; Han, G. Bioorg. Med. Chem. Lett. 2006, 16(15), 4068. https://doi.org/10.1016/j.bmcl.2006.04.091
  14. Kim, H. M.; Ryu, D. K.; Choi, Y.; Park, B. W.; Lee, K.; Han, S. B.; Lee, C. W.; Kang, M. R.; Kang, J. S.; Boovanahalli, S. K.; Park, S. K.; Han, J. W.; Chun, T. G.; Lee, H. Y.; Nam, K. Y.; Choi, E. H.; Han, G. J. Med. Chem. 2007, 50(11), 2737. https://doi.org/10.1021/jm0613828
  15. Hagler, A. T.; Lifson, S.; Dauber, P. J. Am. Chem. Soc. 1979, 101(18), 5122. https://doi.org/10.1021/ja00512a002
  16. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Nature 1999, 401(6749), 188. https://doi.org/10.1038/43710
  17. Stote, R. H.; Karplus, M. Proteins 1995, 23(1), 12. https://doi.org/10.1002/prot.340230104
  18. Liu, X.; Tu, M.; Kelly, R. S.; Chen, C.; Smith, B. J. Drug Metabolism and Disposition 2004, 32(1), 132. https://doi.org/10.1124/dmd.32.1.132

Cited by

  1. Property-Based Optimization of Hydroxamate-Based γ-Lactam HDAC Inhibitors to Improve Their Metabolic Stability and Pharmacokinetic Profiles vol.55, pp.23, 2012, https://doi.org/10.1021/jm3009376
  2. Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability vol.8, pp.2, 2013, https://doi.org/10.1002/cmdc.201200529
  3. Lactam-Based HDAC Inhibitors for Anticancer Chemotherapy: Restoration of RUNX3 by Posttranslational Modification and Epigenetic Control vol.9, pp.3, 2014, https://doi.org/10.1002/cmdc.201300393
  4. Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents vol.20, pp.3, 2015, https://doi.org/10.3390/molecules20033898
  5. Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis vol.6, pp.5, 2015, https://doi.org/10.1021/acsmedchemlett.5b00062
  6. Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries vol.28, pp.3, 2017, https://doi.org/10.1080/1062936X.2017.1294198
  7. Recent Studies on HDAC Inhibitors Acting against Prostate Cancer vol.16, pp.1, 2020, https://doi.org/10.2174/1573408016666200402092557
  8. Development of classification models for identification of important structural features of isoform-selective histone deacetylase inhibitors (class I) vol.24, pp.4, 2020, https://doi.org/10.1007/s11030-019-10013-0